An integrated assessment of the ADME properties of the CDK4/6 Inhibitor ribociclib utilizing preclinical in vitro, in vivo, and human ADME data

James, AD; Schiller, H; Marvalin, C; Jin, Y; Borell, H; Roffel, AF; Glaenzel, U; Ji, Y; Camenisch, G

James, AD (corresponding author), Novartis Inst Biomed Res, PK Sci ADME, Fabrikstr 14, CH-4002 Basel, Switzerland.

PHARMACOLOGY RESEARCH & PERSPECTIVES, 2020; 8 (3):

Abstract

Ribociclib (LEE011, Kisqali (R)) is a highly selective small molecule inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6), which has been approved ......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索